Prior authorization required — use preferred rituximab products first

Prior authorization is required for intravenous (IV) rituximab for non-oncologic indications; for Blue Cross of Idaho commercial plan members, requests should be for a preferred product (Riabni, Ruxience, or Truxima) unless the member has a documented contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products. Dosing must be initiated in accordance with FDA-approved labeling and/or accepted drug compendia.

• Preferred products named: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs).
• Exceptions: documented contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products.
• Dosing must follow FDA labeling or accepted compendia.

Verify line‑of‑business applicability

This policy may not apply to all lines of business; benefit applicability and prior authorization requirements can vary by plan (examples include the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self‑insured groups). Confirm member-specific benefit plan applicability before requesting authorization.

• Benefit exceptions listed: Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, certain self‑insured groups.

Prior authorization — process details not in bibliographic sections

The policy text in bibliographic sections does not state additional prior authorization process details beyond the medical‑necessity criteria; use the policy’s stated initial and continuing criteria and member plan rules when preparing an authorization request.

• Policy history notes adoption and requirement to meet initial and continuing criteria for coverage (see policy history).

Include HCPCS/Q‑codes on prior authorization requests

Reference HCPCS/Q‑codes for rituximab and its biosimilars on authorization requests and claims: J9312, J9311, Q5115, Q5119, and Q5123 are listed in the policy coding section and should be used as applicable when submitting coverage requests.

• HCPCS/Codes listed in policy: J9312; J9311; Q5115 (Truxima); Q5119 (Ruxience); Q5123 (Riabni).
• The policy states that inclusion of a code does not guarantee coverage and benefit determinations are subject to member‑specific plan documentation.

Prior authorization required when seeking coverage — meet initial/continuation criteria

IV rituximab was added to the prescription drug section and requires that requests meet the policy’s initial and continuing treatment criteria to be considered medically necessary; submit supporting documentation that the requested use meets those criteria.

• New policy adoption effective 03/01/2026 adds IV rituximab for non‑oncologic indications to the prescription drug section.
• Initial and continuing criteria must be met for coverage determination.

Preferred product requirement — start with named biosimilars for commercial members

Commercial members should be started on preferred rituximab biosimilars (Riabni, Ruxience, Truxima); use of a non‑preferred rituximab product requires documentation of contraindication, intolerance, adverse response, or inadequate therapeutic response to all preferred products.

• Preferred biosimilars named in the policy: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs).
• Documentation required to support use of non‑preferred agent: contraindication, intolerance, adverse response, or inadequate therapeutic response to preferred products.

Clinical sequencing / combination therapy restriction

There is limited data on concomitant use of rituximab with other biologic agents and with disease‑modifying antirheumatic drugs (other than methotrexate) for certain indications; the policy therefore restricts use of rituximab in combination with other biologic DMARDs, targeted synthetic DMARDs, or other immunomodulators (see Appendices).

• Policy states limited data on concomitant use in RA, GPA, MPA, and pemphigus vulgaris.
• Policy explicitly requires rituximab NOT be used in combination with other biologic or targeted synthetic DMARDs or other immunomodulators.

No step‑therapy rules present in cited sections

The policy’s provided excerpts do not include step therapy rules; specific step therapy steps or enforced sequencing are not present in the cited bibliographic fragments.

• Policy references lists of DMARDs and methotrexate contraindications to inform prior‑therapy considerations, but explicit step rules are not shown in these chunks.

DMARD lists inform prior‑therapy and step considerations

Policy appendices list conventional, biologic, and targeted synthetic DMARDs that inform prior failure/intolerance requirements for rheumatologic indications; when prior‑therapy requirements are relevant, include documentation of trials or contraindications to the listed DMARDs.

• Appendix 1 lists conventional DMARDs (e.g., methotrexate, leflunomide, mycophenolate, cyclosporine, azathioprine, cyclophosphamide, hydroxychloroquine, sulfasalazine).
• Appendix lists biologic DMARDs (e.g., abatacept, adalimumab, infliximab, tocilizumab, rituximab) and targeted synthetic DMARDs (e.g., tofacitinib, baricitinib, upadacitinib).

Required documentation — show indication and prior‑therapy history

Submit documentation with authorization requests that the patient meets the indication‑specific criteria in the policy, and that prior trial/failure or documented contraindication or intolerance to preferred products has occurred when required.

• Document which preferred products were tried and the clinical reason for switching (e.g., intolerance, contraindication, inadequate response).
• Include evidence that the requested use meets the indication‑specific criteria described in the policy.

Administration and safety documentation required

Administer IV rituximab in a clinical setting by a healthcare professional with appropriate medical support to manage severe infusion reactions; document monitoring and any management of infusion reactions and boxed‑warning risks in the medical record.

• Policy states rituximab should be administered by a health care professional with appropriate medical support to manage severe and potentially fatal infusion reactions.
• Boxed warnings include fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation, and PML—document monitoring and safety measures accordingly.

Coding guidance — codes are for reference; confirm member coverage

Coding guidance is provided for reference only: inclusion of a code in the policy does not guarantee coverage; follow member‑specific benefit plan documentation and the written medical policy when submitting claims or authorization requests.

• Policy caution: inclusion/exclusion of codes does not imply coverage or reimbursement eligibility.
• Providers must follow member‑specific plan terms and other applicable policies.

Include ICD‑10 diagnosis and transplant status codes on requests

Include appropriate ICD‑10 diagnosis and, when applicable, transplant status codes from the policy appendices with prior authorization requests and claims; the policy provides extensive diagnosis and transplant status code lists in the coding section.

• ICD‑10 diagnosis ranges and transplant status codes (e.g., T86.x series, Z94.0, Z94.81) are listed in the policy coding appendices.
• Attach the relevant diagnosis and transplant status codes that support medical necessity when submitting requests.

Denial triggers — active infections and non‑preferred agents

Requests may be considered not medically necessary (denied) if the individual has active or untreated latent tuberculosis, active hepatitis B, other active serious infections, a history of recurrent infections, or if the request is for a non‑preferred medication without meeting the policy exceptions.

• Policy explicitly lists active/untreated latent TB, hepatitis B, and other active serious infections as contraindications that may make requests not medically necessary.
• Requests for non‑preferred medications are considered not medically necessary unless policy exceptions are met.

Benefit line exclusions can cause denial

Coverage may be excluded based on the member’s line of business; check whether the member’s plan (e.g., FEP, Medicare Supplement, Medicare Advantage, Medicaid, certain self‑insured groups) is subject to this policy or excluded prior to authorization submission.

• If the member’s line of business is excluded, the request may be denied on that basis.

Code inclusion does not guarantee coverage

The presence of a code in the policy does not guarantee coverage for a given member; coverage determinations remain subject to the member‑specific benefit plan and the written coverage position in the medical policy.

• Policy statement: inclusion of a code does not guarantee or imply any right to member coverage or provider reimbursement.

Medical necessity requirement — failure to meet criteria risks denial

Coverage will be denied if IV rituximab does not meet the policy’s specified medical necessity criteria; ensure all initial and continuing criteria in the policy are met and documented to avoid denial.

• Policy history and continuation sections reiterate that initial and continuing treatment criteria must be met for medical necessity determinations.
• Requests not meeting the criteria are considered not medically necessary.

IV rituximab covered under medical benefit

Intravenous rituximab for non‑oncologic indications is covered under the medical benefit and should be administered in an infusion setting per the policy.

Administer in setting with medical support

Rituximab must be administered by IV infusion in settings with appropriate medical support (infusion center, hospital outpatient, or office) to manage severe infusion reactions.

• Administered by a health care professional with appropriate medical support to manage severe and potentially fatal infusion reactions
• Settings include infusion center, hospital outpatient, or office

No explicit site‑of‑care restrictions in citations

The cited sections do not specify explicit site‑of‑care restrictions; use the policy guidance that rituximab is an IV infusion with setting considerations implied.

Infusion‑setting considerations implied

Policy pertains to IV rituximab and implies infusion‑setting considerations; follow the medical benefit policy for site‑of‑care decisions.

Preferred rituximab products for commercial members

Blue Cross of Idaho commercial plan members should be started on preferred rituximab biosimilars (Riabni, Ruxience, Truxima) per the policy’s biosimilar preference statement.

• Preferred biosimilars: Riabni, Ruxience, Truxima

Biosimilarity and HCPCS codes provided

Biosimilarity for Riabni, Ruxience, and Truxima has been demonstrated as described in their full prescribing information; the policy lists corresponding HCPCS/Q‑codes for these products.

• Biosimilarity statement per Full Prescribing Information
• HCPCS/Q‑codes listed for biosimilars (Q5115, Q5119, Q5123)